<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320073</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0509</org_study_id>
    <secondary_id>CDR0000550148</secondary_id>
    <nct_id>NCT00320073</nct_id>
  </id_info>
  <brief_title>Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors</brief_title>
  <official_title>A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Erlotinib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving vinflunine together with erlotinib or pemetrexed may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vinflunine when&#xD;
      given together with erlotinib or pemetrexed in treating patients with unresectable or&#xD;
      metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Define the maximum tolerated dose (MTD) of vinflunine and pemetrexed disodium in&#xD;
           patients with unresectable or metastatic solid tumors.&#xD;
&#xD;
        -  Define the MTD of vinflunine and erlotinib hydrochloride in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the preliminary safety and efficacy (reported descriptively per patient&#xD;
           response; tumor specific response rate reported if applicable) of these regimens.&#xD;
&#xD;
        -  Correlate CYP3A4 activity, as measured by midazolam clearance, with vinflunine plasma&#xD;
           clearance.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, dose-escalation study. Patients are assigned to&#xD;
      1 of 2 treatment groups.&#xD;
&#xD;
        -  Group 1: Patients receive pemetrexed disodium IV over 10 minutes and vinflunine IV over&#xD;
           20 minutes on day 1.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of pemetrexed disodium and vinflunine until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Additional patients may&#xD;
      be treated at the MTD.&#xD;
&#xD;
        -  Group 2: Patients receive vinflunine IV over 20 minutes on day 1 and oral erlotinib&#xD;
           hydrochloride once daily on days 2-21 of course 1 and on days 1-21 of all subsequent&#xD;
           courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride and vinflunine&#xD;
      until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or&#xD;
      2 of 6 patients experience dose-limiting toxicity. Additional patients may be treated at the&#xD;
      MTD.&#xD;
&#xD;
      In both groups, courses repeat every 21 days in the absence of unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected on day 1 of course 1 for pharmacodynamic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30-40 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vinflunine and pemetrexed disodium</measure>
    <time_frame>1 year</time_frame>
    <description>The MTD is defined as the dose cohort where approximately 0.20 of patients experience DLT. Standard &quot;groups of three&quot; phase I dose escalation design will be used in each arm. Each dose cohort will accrue a minimum of three patients.The estimated MTD is the dose level below the dose that induced dose limiting toxicity (DLT) in one third or more of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vinflunine and continuously dosed erlotinib</measure>
    <time_frame>1 year</time_frame>
    <description>The MTD is defined as the dose cohort where approximately 0.20 of patients experience DLT. Standard &quot;groups of three&quot; phase I dose escalation design will be used in each arm. Each dose cohort will accrue a minimum of three patients.The estimated MTD is the dose level below the dose that induced dose limiting toxicity (DLT) in one third or more of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vinflunine and intermittently dosed erlotinib</measure>
    <time_frame>1 year</time_frame>
    <description>The MTD is defined as the dose cohort where approximately 0.20 of patients experience DLT. Standard &quot;groups of three&quot; phase I dose escalation design will be used in each arm. Each dose cohort will accrue a minimum of three patients.The estimated MTD is the dose level below the dose that induced dose limiting toxicity (DLT) in one third or more of patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinflunine, Erlotinib, Ondansetron, Midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>75 mg to 150mg</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>Pemetrexed is administered intravenously over 10 minutes, every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinflunine</intervention_name>
    <description>Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumors&#xD;
&#xD;
               -  Advanced/unresectable or metastatic disease&#xD;
&#xD;
          -  Refractory to standard therapy OR no standard therapy exists&#xD;
&#xD;
          -  No lymphoma&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease is defined as at least one target lesion measuring ≥ 20 mm by&#xD;
                  conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Evaluable disease includes ascites, pleural effusion, bone metastases, pulmonary&#xD;
                  lymphangitic spread, and lesions not meeting above criteria as measurable&#xD;
&#xD;
                    -  Patients with clinically significant ascites or pleural effusions that&#xD;
                       cannot be controlled by drainage are not eligible&#xD;
&#xD;
          -  Brain metastases allowed if CNS-directed treatment has been given, patient has been&#xD;
             off CNS-directed therapy for &gt; 3 months, and CNS disease has been clinically and&#xD;
             radiographically stable for at least 8 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Patients assigned to group 1 with creatinine clearance 45-80 mL/min must be able&#xD;
                  to withhold NSAIDS during pemetrexed disodium administration&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN) OR ≤ 5 times ULN if due to known&#xD;
             liver metastases&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No poorly controlled hypertension&#xD;
&#xD;
          -  No prior allergic reaction to any vinca alkaloid&#xD;
&#xD;
          -  No uncontrolled active infection or severe illness&#xD;
&#xD;
          -  Able to receive vitamin B12 and folate supplementation and dexamethasone during&#xD;
             chemotherapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after last&#xD;
             dose of chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy, investigational agents, or surgery&#xD;
&#xD;
          -  Concurrent cytochrome P450/CYP3A4 inducers or inhibitors are allowed provided patient&#xD;
             has been on a stable dose for ≥ 2 weeks prior to study entry&#xD;
&#xD;
          -  No concurrent ketoconazole, itraconazole, ritonavir, amprenavir, or indinavir&#xD;
&#xD;
          -  No concurrent enzyme-inducing antiepileptic drugs (EIAEDs) (e.g., phenytoin,&#xD;
             carbamazepine, phenobarbital, primidone, or oxcarbazepine) for patients assigned to&#xD;
             group 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth C. Dees, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

